

# Medical History, Physical Evaluation, and Risk Assessment

Lauren L. Patton, DDS

## Abbreviations used in this chapter

ADA	American Dental Association
ASA	American Society of Anesthesiologists
GERD	gastroesophageal reflux disease
PS	physical status

## I. Background

The US and global population demographics are constantly changing, chronic diseases are becoming more prevalent, new medications are being developed and brought to the market, and new and reemerging infectious diseases are being identified. The average life expectancy in the USA increased from 70.0 years to 76.2 years for males and from 77.4 years to 81.0 years for females in the 30 years between 1980 and 2010.<sup>1</sup> With this increased life expectancy comes an increase in chronic medical conditions. Americans' use of prescription drugs has grown over the past half-century due to many factors, with

almost one-half of the US population taking at least one prescription drug in the preceding month and 1 in 10 taking five or more drugs.<sup>1</sup>

More patients seeking oral health care have underlying medical conditions that may alter oral health status, treatment approaches, and outcomes. The challenges of medical history information gathering and risk assessment required for safe dental treatment planning and care delivery will be discussed and presented in a practical manner applicable to day-to-day needs of the general practice dentist. There are four key considerations that serve as a framework for assessing and managing the risks of dental care used in this book, although additional considerations may be relevant for certain medical conditions. The key considerations are impaired hemostasis, susceptibility to infections, drug actions/interactions, and ability to tolerate the stress of dental care. The potential for the dental practice to encounter different types of medical emergencies is related to the patient's medical health, adequacy of management, and stress tolerance.

## Four key risks of dental care

- a query about prosthetic joint replacements and any prior antibiotic recommendations by a physician or dentist and name and contact phone number of recommending provider;
- a query about the four cardiac disease conditions recommended for antibiotic coverage for prevention of infective endocarditis;
- a query of women about current pregnancy, nursing status, or birth control pills or hormonal therapy.

There is a Child Health/Dental History Form (see Fig. 1.2) also available from the ADA that focuses on inherited, developmental, infectious, and acquired diseases of importance to dental health-care delivery for children.

Family history can facilitate awareness of need to screen for and engage in prevention

efforts for common diseases (such as heart disease, cancer, diabetes) and rarer diseases (including hemophilia, sickle cell anemia, and cystic fibrosis). The Surgeon General has created a family health history initiative to facilitate family discussion of inherited diseases. This free tool, found at <https://familyhistory.hhs.gov>, will allow patients and providers to download the form to gather relevant health information for patients to share with providers. Whether disease etiology derives from genetics, environment, learned behaviors, or a combination of factors, many health conditions, such as propensity to hypertension, may run in families.

### III. Physical Evaluation and Medical Risk Assessment

The initial and ongoing assessment of patient medical risk in dental practice has several purposes:

- To minimize risk of adverse events in the dental office resulting from dental treatment.
- To identify patients who need further medical assessment and management.
- To identify patients for whom specific peri-operative therapies or treatment modifications will minimize risk, including postponing elective treatment.
- To identify appropriate anesthetic technique, intraprocedure monitoring, and postprocedure management.
- To discuss treatment procedures with patients, outlining risks and benefits, in order to obtain informed consent and determine need for additional anxiolysis.

One of the most common medical risk assessment frameworks is the American Society of Anesthesiologists (ASA) Physical Status Score<sup>2</sup> used to classify patients for anesthesia risk (Table 1.1 A medical risk-related health history is important to detect medical problems in patients. While across all ages most (78%) dental patients are healthy ASA 1 patients, the

**Child Health/Dental History Form**

ADA  
American Dental Association  
www.ada.org

Patient's Name: LAST FIRST MIDDLE Initials Date of Birth: \_\_\_\_\_

Parent's Name: LAST FIRST MIDDLE Address: \_\_\_\_\_

Phone: \_\_\_\_\_

Have you (the parent/guardian) or the patient had any of the following diseases or problems? (If you answer yes to any of the three items above, please stop and return this form to the receptionist.)

1. Aids: HIV/AIDS 2. Rheumatoid arthritis 3. Chronic hepatitis 4. Diabetes 5. Epilepsy 6. Heart disease 7. Kidney disease 8. Liver disease 9. Lung disease 10. Mental illness 11. Multiple sclerosis 12. Muscular dystrophy 13. Sickle cell anemia 14. Scurvy 15. Tuberculosis 16. Ulcers 17. Varicella (chickenpox) 18. Warts 19. Xeroderma pigmentosum

Has the child had any history of or conditions related to any of the following?

1. Allergies 2. Bleeding disorders 3. Celiac disease 4. Cleft lip/palate 5. Crohn's disease 6. Deafness 7. Diabetes 8. Epilepsy 9. Heart disease 10. Kidney disease 11. Liver disease 12. Lung disease 13. Mental illness 14. Multiple sclerosis 15. Muscular dystrophy 16. Sickle cell anemia 17. Scurvy 18. Tuberculosis 19. Ulcers 20. Varicella (chickenpox) 21. Warts 22. Xeroderma pigmentosum

Please list the name and phone number of the child's physician: \_\_\_\_\_

**Child's History**

1. Is the child taking any prescription and/or over the counter medications or vitamin supplements at this time? Yes No

2. If yes, please list: \_\_\_\_\_

3. Is the child allergic to any medications, i.e., penicillin, antibiotics, or other drugs? If yes, please explain: \_\_\_\_\_

4. Is the child allergic to anything else, such as certain foods? If yes, please explain: \_\_\_\_\_

5. How would you describe the child's feeding history? \_\_\_\_\_

6. Has the child ever had a seizure? If yes, when? Please describe: \_\_\_\_\_

7. Has the child ever been hospitalized? \_\_\_\_\_

8. Does the child have a history of any other illness? If yes, please list: \_\_\_\_\_

9. Has the child ever received a general anesthetic? \_\_\_\_\_

10. Does the child have any dental problems? \_\_\_\_\_

11. Has the child ever had a blood transfusion? \_\_\_\_\_

12. Is the child physically, mentally, or emotionally impaired? \_\_\_\_\_

13. Does the child experience excessive bleeding when cut? \_\_\_\_\_

14. Is the child currently being treated for any illness? \_\_\_\_\_

15. Is the child's first visit to a dentist? If yes, what was the date of the last dental visit? Date: \_\_\_\_\_

16. Has the child had any problem with dental treatment in the past? \_\_\_\_\_

17. Has the child ever had dental radiographs (X-rays) taken? \_\_\_\_\_

18. Has the child ever received any radiation to the mouth, head or neck? \_\_\_\_\_

19. Has the child had any problems with the eruption or shedding of teeth? \_\_\_\_\_

20. Has the child had any orthodontic treatment? \_\_\_\_\_

21. What type of water does your child drink? City water Well water Bottled water Filtered water

22. Does the child take fluid (or supplements)? \_\_\_\_\_

23. Is fluid type toothpaste used? \_\_\_\_\_

24. How many times are the child's teeth brushed per day? \_\_\_\_\_ When are the teeth brushed? \_\_\_\_\_

25. Does the child push, suck, thumb, finger or pacifier? \_\_\_\_\_

26. At what age did the child stop sucking? Age: \_\_\_\_\_ Breast feeding? Age: \_\_\_\_\_

27. Does the child participate in any recreational activities? \_\_\_\_\_

NOTE: Both doctor and patient are encouraged to discuss any and all relevant patient health issues prior to treatment. I certify that I have read and understood the above. I acknowledge that my signature, name, about inquiries set forth above have been entered in my chart. I understand my consent, or any other member of my staff, shall be given for any action they follow do not constitute or create any omission that may have made in the completion of this form.

Parent/Guardian's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

For completion by dentist

Comments: \_\_\_\_\_

For Office Use Only: Examined by: \_\_\_\_\_ Reviewed by: \_\_\_\_\_ Diagnosed by: \_\_\_\_\_ Treated by: \_\_\_\_\_

Date: \_\_\_\_\_

© American Dental Association, 2006  
Form S707

To handle all patient care or general anesthesia

**Figure 1.2** ADA Child Health/Dental History Form S707, copyright 2006. American Dental Association. Reproduced with permission of the American Dental Association.

**Table 1.1** ASA Physical Status (PS) Classification,<sup>2</sup> Activity Characteristics/Treatment Risk, and Medical Examples

ASA Physical Status	Activity Characteristics/Treatment Risk	Medical Examples
ASA PS 1 A normal healthy patient.	<ul style="list-style-type: none"> <li>• Patient is able to walk up one flight of stairs or two level city blocks without distress.</li> <li>• Little or no anxiety.</li> <li>• <b>Little or no risk during treatment.</b></li> </ul>	<ul style="list-style-type: none"> <li>• Healthy 20-year-old.</li> </ul>
ASA PS 2 A patient with mild systemic disease.	<ul style="list-style-type: none"> <li>• Patient has mild to moderate systemic disease or is a healthy ADA PS1 patient who demonstrated a more extreme anxiety and fear towards dentistry.</li> <li>• Patient is able to walk up one flight of stairs or two level city blocks, but will have to stop after completion of the exercise because of distress.</li> <li>• <b>Minimal risk during treatment.</b></li> </ul>	<ul style="list-style-type: none"> <li>• ASA 1 with respiratory condition, active allergies, dental phobia, or pregnancy.</li> <li>• Well diet or oral hypoglycemic agent—controlled diabetic.</li> <li>• Well-controlled asthmatic.</li> <li>• Well-controlled epileptic.</li> <li>• Well-controlled hypertensive not on medication.</li> </ul>
ASA PS 3 A patient with severe systemic disease.	<ul style="list-style-type: none"> <li>• Patient has severe systemic disease that limits activity, but is not incapacitating.</li> <li>• Patient is able to walk up one flight of stairs or two level city blocks, but will have to stop on the way because of distress.</li> <li>• <b>If dental care is indicated, stress reduction protocol and other treatment modifications are indicated.</b></li> </ul>	<ul style="list-style-type: none"> <li>• Well-controlled hypertensive on medication.</li> <li>• Well-controlled diabetic on insulin.</li> <li>• Slight chronic obstructive pulmonary disease.</li> <li>• Thirty days or more ago history of myocardial infarction or cerebrovascular accident or congestive heart failure.</li> </ul>
ASA PS 4 A patient with severe systemic disease that is a constant threat to life.	<ul style="list-style-type: none"> <li>• Patient has severe systemic disease that limits activity and is a constant threat to life.</li> <li>• Patient is unable to walk up one flight of stairs or two level city blocks. Distress is present even at rest.</li> <li>• <b>Patient poses significant risk during treatment.</b></li> <li>• <b>Elective dental care should be postponed until such time as the patient's medical condition has improved to at least an ASA P3 classification.</b></li> <li>• <b>Emergent dental care may be best provided in a hospital setting in consultation with the patient's physician team.</b></li> </ul>	<ul style="list-style-type: none"> <li>• History of unstable angina, myocardial infarction, or cerebrovascular accident in last 30 days.</li> <li>• Severe congestive heart failure.</li> <li>• Moderate to severe chronic obstructive pulmonary disease.</li> <li>• Uncontrolled hypertension.</li> <li>• Uncontrolled diabetes.</li> <li>• Uncontrolled epilepsy or seizure disorder.</li> </ul>

(Continued)

**Table 1.1** (Continued)

ASA Physical Status	Activity Characteristics/Treatment Risk	Medical Examples
ASA PS 5 A moribund patient who is not expected to survive without the operation.	<ul style="list-style-type: none"> <li>Hospitalized patient in critical condition.</li> <li><b>Emergency dental care to eliminate acute oral disease is provided only when deemed a component of lifesaving surgery.</b></li> </ul>	<ul style="list-style-type: none"> <li>Terminal illness often of acute onset.</li> </ul>
ASA PS 6 A declared brain-dead patient whose organs are being removed for donor purposes.	<ul style="list-style-type: none"> <li><b>Dental care not warranted.</b></li> </ul>	<ul style="list-style-type: none"> <li>Brain dead.</li> </ul>

Source: Adapted from American Society of Anesthesiologists. Accessed 2014.<sup>2</sup>

percentage that is of higher ASA physical status (ASA 2–ASA 6) increases with increasing age.<sup>3</sup> By age 65, only 55% of adults remain healthy ASA 1. Medical conditions such as cardiovascular disease and hypertension account for a high proportion of ASA 3 and ASA 4 patients.

Up to a third of dental patients who answer yes to “Are you in good health?” on verification are found to be medically compromised.<sup>4</sup> In a survey of dental patients completing health history forms based on the ADA Health History Form available at the time, the diseases most inaccurately reported or omitted were blood disorders, cardiovascular disease, and diabetes.<sup>4</sup> The authors concluded that using both a self-administered questionnaire and dialog on the health history might improve communication.

There are several physical signs or clues that indicate a patient who reports having received no medical care might not truly be healthy, but rather simply not accessing medical care:

- age over 40 years;
- obese or cachectic body habitus;
- low energy level;
- abnormal skin coloration;
- poor oral hygiene;
- tobacco smoking.

Often, the patient’s response to the question “Can you walk up two flights of stairs without stopping to catch your breath?” can indicate general cardiovascular and pulmonary health status.

Vital signs, including blood pressure and heart rate (pulse), should be assessed at each visit. The other vital signs of temperature, respiration rate, and pain score may be useful additional signs of current health. A focused review of systems should allow a cursory review of the patient’s recent state of health, focusing on recent changes and be tailored to the patient and planned dental procedure(s).

#### Brief review of systems

- **General:** fever, chills, night sweats, weakness, fatigue
- **Cardiovascular:** reduced exercise tolerance, chest pain, orthopnea, ankle swelling, claudication
- **Pulmonary:** upper respiratory infection symptoms—productive cough, bronchitis, wheezing
- **Hematological:** bruising, epistaxis
- **Neurological:** mental status changes, transient ischemic attacks, numbness, paresis
- **Endocrine:** polydipsia, polyuria, polyphagia, weight gain/loss

Under each medical topic, we present “key questions to ask the patient” to allow improved risk assessment and determination of dental treatment modifications.

### Communication with the Patient’s Physician

Evidence-based dental practice relies on patients, physicians, and dentists working together collaboratively to use scientific evidence, clinician experience, and patients’ values/preferences in the decision-making process to customize an individual treatment plan to improve patient care. The dentist should consult with the patient’s physician to clarify areas of the patient’s health that are unclearly communicated by the patient who is a poor historian or where a reported medical condition is monitored and the patient does

not have complete information. This includes consultations about current laboratory assessments, prescribed medications, and other medical and surgical therapies, and coordination of care. Under each medical topic, we present “key questions to ask the physician” to facilitate improved communication and coordination of care.

### Influence of Systemic Disease on Oral Disease and Health


The health history should give the dentist an appreciation of oral conditions that may have a systemic origin and thus require systemic management as an aspect of treatment. Several abnormal signs and symptoms in the facial region, oral structures, and teeth with systemic origin are listed in Table 1.2 and illustrated in Figs 1.3, 1.4, 1.5, and 1.6.

Table 1.2 Facial, Oral, and Dental Signs Possibly Related to Medical Disease or Therapy	
	Possible Causative Medical Disease or Therapy
<b>Facial Signs</b>	
<b>Cachexia</b>	Wasting from cancer, malnutrition, HIV/AIDS
<b>Cushingoid facies</b>	Cushing syndrome, steroid use
<b>Jaundiced skin/sclera</b>	Liver cirrhosis
<b>Malar rash</b>	Systemic lupus erythematosus
<b>Ptosis</b>	Myasthenia gravis
<b>Taught skin and microstomia</b>	Scleroderma, facial burns
<b>Telangiectasias</b>	Liver cirrhosis
<b>Weak facial musculature</b>	Neurologic disorder, facial nerve palsy, tardive dyskinesia, myasthenia gravis
<b>Oral Signs</b>	
<b>Bleeding, ecchymosis, petechiae</b>	Thrombocytopenia, thrombocytopathy, hereditary coagulation disorder, liver cirrhosis, aplastic anemia, leukemia, vitamin deficiency, drug induced
<b>Burning mouth/tongue</b>	Anemia, vitamin deficiency, candida infection, salivary hypofunction, primary or secondary neuropathy
<b>Dentoalveolar trauma</b>	Interpersonal violence, accidental trauma, seizure disorder, gait/balance instability, alcoholism
<b>Drooling</b>	Neoplasm; neurologic: amyotrophic lateral sclerosis, Parkinson’s disease cerebrovascular accident, cerebral palsy; medications (e.g., tranquilizers, anticonvulsants, anticholinesterases)
(Continued)	



**Table 1.2** (Continued)

	<b>Possible Causative Medical Disease or Therapy</b>
<b>Dry mucosa</b>	Drug-induced xerostomia, salivary hypofunction from Sjogren's syndrome, diabetes or head and neck cancer radiation therapy
<b>Gingival overgrowth</b>	Leukemia, drug induced (phenytoin, cyclosporine, calcium-channel blockers)
<b>Hard tissue enlargements</b>	Neoplasm, acromegaly, Paget's disease, hyperparathyroidism
<b>Mucosal discoloration of hyperpigmentation</b>	Addison's disease, lead poisoning, liver disease, melanoma, drug induced (e.g., zidovudine, tetracycline, oral contraceptives, quinolones)
<b>Mucosal erythema and ulceration</b>	Cancer chemotherapy, uremic stomatitis, autoimmune disorders (systemic lupus, Bechet's syndrome), vitamin deficiency, Celiac disease, Crohn's disease, drug induced, self-injurious behavior
<b>Mucosal pallor</b>	Anemia, vitamin deficiency
<b>Nondental source oral/jaw pain</b>	Referred pain (e.g., cardiac, neurologic, musculoskeletal), including myofascial and temporomandibular joints; drug induced (e.g., vincristine chemotherapy); primary neoplasms; cancer metastases; sickle cell crisis pain; primary or secondary neuropathies
<b>Opportunistic infections</b>	Immune suppression from HIV, cancer chemotherapy, hematologic malignancy; primary immune deficiency syndromes; poorly controlled diabetes; stress
<b>Oral malodor</b>	Renal failure, respiratory infections, gastrointestinal conditions
<b>Osteonecrosis</b>	Radiation to the jaw; current or prior use of antiresorptive agents such as bisphosphonates or receptor activator of NFκB ligand inhibitors, and certain cancer antiangiogenic agents
<b>Poor wound healing</b>	Immune suppression from HIV, cancer chemotherapy, primary immune deficiency syndromes; poorly controlled diabetes; malnutrition; vitamin deficiency
<b>Soft tissue swellings</b>	Neoplasms, amyloidosis, hemangioma, lymphangioma, acromegaly, interpersonal violence or accidental trauma
<b>Trismus</b>	Neoplasm, post-radiation therapy, arthritis, post-traumatic mandible condyle fracture
<b>Dental Signs</b>	
<b>Early loss of teeth</b>	Neoplasms, nutritional deficiency (e.g., hypophosphatemic vitamin D resistant rickets, scurvy), hypophosphatasia, histiocytosis X, Hand-Schuller-Christian disease, Papillon-Lefèvre syndrome, acrodynia, juvenile-onset diabetes, immune suppression (e.g., cyclic neutropenia, chronic neutropenia), interpersonal violence or other traumatic injury, radiation therapy to the jaw, dentin dysplasia, trisomy 21-Down syndrome, early-onset periodontitis
<b>Rampant dental caries</b>	Salivary hypofunction from disease (e.g., Sjögren's syndrome), post-radiation, or xerogenic medications; illegal drug use (e.g., methamphetamines); inability to cooperate with oral hygiene and diet instructions
<b>Tooth discoloration</b>	Genetic defects in enamel or dentin (e.g., amelogenesis imperfecta, dentinogenesis imperfect), porphyria, hyperbilirubinemia, drug induced (e.g., tetracycline)
<b>Tooth enamel erosion</b>	Gastroesophageal reflux disease (GERD), bulimia nervosa



**Figure 1.3** Cachexia due to HIV wasting syndrome.



**Figure 1.5** Taught facial skin and microstomia due to systemic sclerosis (scleroderma).



**Figure 1.4** Cushingoid faces and malar rash due to systemic lupus erythematosus and chronic steroid use.



**Figure 1.6** Facial port-wine stain of Sturge-Weber syndrome (encephalotrigeminal angiomatosis).

The astute dental provider also has the opportunity to observe physical and oral conditions that might indicate undiagnosed or poorly managed systemic disease. Examples are oral candidiasis that might indicate a poorly controlled



immune-suppressing medical condition, significant inflammatory periodontal disease as an indicator of poorly controlled diabetes, gingival enlargements that are leukemic infiltrates, or mucosal pallor indicating an anemia. Tooth erosion in adolescent females might raise suspicion for an eating disorder such as bulimia, while in older adults might indicate a history of GERD. Acutely declining oral hygiene and self-care in the elderly might indicate physical disability or mental decline with dementia onset. On panoramic radiographs, carotid artery calcifications may be detected that correlate with hypertension, hyperlipidemia, and heart disease, and may warrant patient referral for further medical evaluation.<sup>5</sup> Dental radiographic signs suggestive of systemic disease or therapy are shown in Table 1.3.

### Framework for Key Risks of Dental Care

The scope of dental practice is wide, encompassing aspects of both medicine and surgery.

Dental care plans and individual procedures vary in their level of invasiveness and risk to the patient. Systemic health may alter the healing response to surgery, response to and effectiveness of surgical and nonsurgical therapies, and risks of precipitating a medical emergency.

### Impaired hemostasis

A bleeding risk assessment must consider both patient-related factors of medical history, medications, review of systems, and physical exam assessment for inherited and acquired defects of hemostasis, as well as procedure-related factors including intensity of the planned surgery. Hemostatic risk can result from inherited or acquired disorders and may necessitate medical support management by a hematologist or other physician, particularly for surgical procedures. When more than one of the four phases of hemostasis is defective, the clinical bleeding response from surgery is generally more severe than when there is an isolated defect in only one phase of hemostasis.

**Table 1.3** Dental Radiographic Signs Suggestive of Medical Disease or Therapy

Dental Radiographic Signs	Possible Causative Medical Disease or Therapy
Carotid artery calcification	Carotid arteritis, stroke or transient ischemic attack-related disease, hypertension, hyperlipidemia, heart disease
Condyle/temporomandibular joint articular space destruction	Rheumatoid arthritis, osteoarthritis
Marrow hyperplasia, increased spacing of bony trabeculae, generalized radiolucency	Sickle cell anemia, osteopenia, osteoporosis, malnutrition, secondary hyperparathyroidism from renal disease or renal osteodystrophy
Marrow hypoplasia, generalized increased density or radiopacity	Osteopetrosis, Paget disease, hypoparathyroidism
Reduced cortical bone density	Primary hyperparathyroidism
Resorption of angle of the mandible	Scleroderma
Well-defined radiolucencies not associated with teeth	Neoplasms, multiple myeloma, metastatic cancer

**The four phases of hemostasis**

- Vascular
- Platelet
- Coagulation
- Metabolic/fibrinolytic

Oral and physical examination findings indicating increased risk for hemostatic defects include the following:

- skin and mucosal petechiae, ecchymoses, or purpura (see Figs 1.7, 1.8, and 1.9);



**Figure 1.7** Petechiae and mucosal pallor due to aplastic anemia.



**Figure 1.8** Petechiae and ecchymoses of tongue and lip due to severe thrombocytopenia.

- skin and mucosal hematomas (see Fig. 1.10);
- spontaneous gingival hemorrhage (see Fig. 1.11);
- hemosiderin staining of calculus on teeth (see Fig. 1.12);
- jaundice of sclera, mucosa, and skin (see Fig. 1.13);
- spider angioma skin stigmata of severe liver disease (see Fig. 1.14).

Anticoagulant medications (warfarin, low-molecular-weight heparins, dabigatran, rivaroxaban, apixaban) and antiplatelet agents (clopidogrel, prasugrel, ticagrelor, ticlopidine, and aspirin/dipyridamole sustained release) are commonly prescribed for cardio-




**Figure 1.9** Purpura of arm skin due to alcoholic cirrhosis.



**Figure 1.10** Hematoma of finger due to severe hemophilia A.



**Figure 1.11** Spontaneous gingival bleeding due to severe thrombocytopenia.



**Figure 1.13** Jaundice of sclera of eye due to severe liver cirrhosis.



**Figure 1.12** Hemosiderin-stained calculus on teeth from chronic oral bleeding due to severe hemophilia A.



**Figure 1.14** Spider angioma of skin due to severe liver disease.

vascular diseases and clotting-prone conditions, and some of the most commonly used over-the-counter analgesic medicines (aspirin, ibuprofen) may alter hemostasis. Dental providers also need to be aware that use of herbal supplements, often not revealed in the health history, can enhance bleeding risk. Four of the

top five supplements (green tea, garlic, ginkgo biloba, and ginseng) taken by dental patients in a dental-school-based study are reported to enhance bleeding risk.<sup>6</sup>

Weighing against the need to discontinue aspirin therapy for dental extractions, a recent case-control study demonstrated no

difference in bleeding outcome from a single tooth extraction for patients on 325 mg daily aspirin compared with those receiving placebo.<sup>7</sup> The small, but fatal, risk of thromboembolic complications of discontinuing antiplatelet therapy for dental surgery, compared with the remote chance of a nonfatal bleeding episode, weighs against interrupting antiplatelet therapy for dental surgery.<sup>8</sup> The informed consent discussion should specifically address the added risk of bleeding and bruising for anyone undergoing surgery while on antiplatelet or anticoagulant medications.

Because of the importance of anticoagulation for certain cardiac conditions, the management of dental patients on warfarin has been controversial with a trend toward little or no modification in warfarin use around the time of dental treatment for most procedures except surgical procedures anticipating significant blood loss.<sup>9</sup> In addition, in an attempt to reduce coronary events after coronary artery stent placement, an advisory group involving representatives from dentistry stresses the importance of maintaining 12 months of dual antiplatelet therapy after placement of a drug-eluting stent and educating patients and health-care providers about hazards of premature discontinuation.<sup>10</sup> This advisory statement also recommends postponing elective dental surgery for 1 year, and considering the continuation of aspirin during the perioperative period in high-risk patients with drug-eluting stents if surgery cannot be deferred.<sup>10</sup>

Local measures to control bleeding—such as pressure, local hemostatic materials, epinephrine, electrocautery, bone wax, surgical stents, and the antifibrinolytic drug  $\epsilon$ -aminocaproic acid 25% syrup—may be used to supplement any modification in the dental management plan. Hemorrhage control might be easier to obtain with local measures when a single tooth is extracted, compared with a

more intense surgery such as removal of all the teeth in an arch.

## Susceptibility to Infection

The oral cavity is host to numerous bacteria and fungi, raising the concern of local infection and the potential for distant hematogenous spread of oral microorganisms. Transient bacteremias of various magnitudes are common as a result of eating, daily oral hygiene, and almost all dental procedures and are generally cleared in less than 30 min. Among patients with chronic periodontitis, a recent study demonstrated that the incidence, magnitude, and bacterial diversity of bacteremia due to flossing (30%) was not significantly different compared with scaling and root planing (43.3%), and both caused the same incidence of viridans streptococcal bacteremia (26.7%).<sup>11</sup> The adverse health impact of transient bacteremias is not fully understood. Antibiotics given before a dental procedure decrease the risk of bacteremia from the oral cavity, but this is of uncertain clinical importance.

Expert panel consensus statements or guidelines exist for antibiotic prophylaxis for invasive dental procedures for patients with several medical conditions, including infectious endocarditis,<sup>12</sup> implanted nonvalvular cardiac devices,<sup>13</sup> and other nonvalvular cardiovascular devices.<sup>14</sup> After years of controversy, the American Academy of Orthopaedic Surgeons and the ADA 2012 guidelines proposed that the practitioner consider changing the long-standing practice of routinely prescribing prophylactic antibiotics for patients with orthopedic implants who undergo dental procedures, that the benefit of oral topical antimicrobials in the prevention of periprosthetic joint infections is inconclusive, and maintenance of good oral hygiene is beneficial.<sup>15</sup> This paper was the first to overtly state that patient preference was an important consideration.<sup>15</sup> Jevsevar<sup>16</sup> created



a doctor–patient shared decision-making tool, including four multiple-choice questions for the patient and a checklist to help determine whether taking an antibiotic prior to dental procedures is prudent or necessary for patients with prosthetic joints. In 2015, the ADA Council on Scientific Affairs, updating the 2012 review, reported their evidence-based clinical guideline for dental practitioners.<sup>17</sup> They recommended: “In general, for patients with prosthetic joint implants, prophylactic antibiotics are not recommended prior to dental procedures to prevent prosthetic joint infection.”<sup>17</sup> They further acknowledged the importance of consideration of the health history, and for some patients with a history of joint complications, the patient’s orthopedic surgeon, in consultation with the patient, may recommend and write a specific antibiotic regimen for a specific patient.<sup>17</sup>

A systematic review of patients with eight medical conditions or medical devices who are often given antibiotics prior to invasive dental procedures found little or no evidence to support this practice or to demonstrate that antibiotic coverage prevents distant site infections for any of these eight groups of patients.<sup>18</sup> The conditions and devices reviewed included cardiac-native heart valve disease; prosthetic heart valves and pacemakers; hip, knee, and shoulder prosthetic joints; renal dialysis shunts; cerebrospinal fluid shunts; vascular grafts; immunosuppression secondary to cancer and cancer chemotherapy; systemic lupus erythematosus; and insulin-dependent (type 1) diabetes mellitus. However, the host defense against bacteria in the blood may be weakened by various diseases and conditions, making antibiotic use for certain at-risk individuals a rational approach to care.

The general paradigm shift occurring in health-care professional advisory statements and guidelines related to concern about distant site infection resulting from dental treatment is to emphasize the importance of the

patient maintaining good oral hygiene and good gingival, periodontal, and dental health as a method of preventing distant site infection rather than using pretreatment antibiotic coverage for many unproven and low-risk conditions or conditions for which treatment of the infection would not be especially morbid.

## Drug Actions/Interactions

Patients with complex medical conditions are likely to be on multiple medications for management of their systemic disease. Pharmaceutical agents taken as directed have both therapeutic (desired) effects and adverse (unwanted) effects. Most adverse effects can be anticipated from the known pharmacology of the drug and tend to be tolerable, although unpleasant. Patients should be informed of the most common side effects of medications and given advice at the time of prescription as to how to manage them.

A large US ambulatory adult population-based phone survey in 1998–1999 indicated that most adults (81%) routinely take at least one medication and many take multiple medications with substantial overlap between use of prescription medications, over-the-counter medications, and herbals/supplements, raising concerns about unintended interactions.<sup>19</sup> The top 25 most commonly used prescription and over-the-counter drugs reported in this study are shown in Table 1.4. Vitamins and minerals are taken by 40% and herbals/supplements by 14% of adults. The most commonly used dietary supplements are shown in Table 1.5. Overall, 16% of prescription medication users also used one or more herbals/supplements, with greatest use among middle-aged women.<sup>19</sup>

In a subsequent study in 2005–2006 of nationally representative community-dwelling older adults (aged 57–85 years) in the USA, 81% used at least one prescription medication, 42% used at least one over-the-counter medication,



**Table 1.4** Top 25 Most Commonly Used Prescription and Over-the-Counter Drugs, 1-Week Prevalence, by Gender/Age [in Years (y)]

Rank	Total Adult Use (%)	Drug <sup>a</sup>	Use in Age Group (%)					
			Men			Women		
			18-44 y	45-64 y	≥65 y	18-44 y	45-64 y	≥65 y
1	23	Acetaminophen	20	16	16	28	25	27
2	17	Ibuprofen	15	13	7	24	22	8
3	17	Aspirin	10	22	39	10	21	23
4	8.1	Pseudoephedrine	8	6	2	12	9	3
5	5.2	<b>Conjugated estrogens</b>	0	0	0	1	21	17
6	4.4	Diphenhydramine hydrochloride	4	3	5	5	6	4
7	4.2	<b>Levothyroxine sodium</b>	<1	2	4	3	9	13
8	4.2	<b>Ethinyl estradiol</b>	0	0	0	14	2	0
9	3.9	Caffeine <sup>b</sup>	3	2	2	6	5	1
10	3.7	<b>Hydrochlorothiazide</b>	1	4	6	1	6	12
11	3.5	Dextromethorphan hydrobromide	4	1	<1	6	3	3
12	3.5	Naproxen	1	3	3	5	4	4
13	2.9	Chlorpheniramine maleate/tannate	2	3	1	4	2	2
14	2.6	<b>Atrovastatin calcium</b>	2	7	7	<1	2	3
15	2.6	<b>Lisinopril</b>	1	3	7	<1	4	7
16	2.6	<b>Medroxyprogesterone acetate</b>	0	0	0	<1	12	4
17	2.5	<b>Loratadine</b>	3	2	0	3	4	1
18	2.3	<b>Furosemide</b>	<1	2	12	0	2	9
19	2.3	Phenylpropanolamine	2	2	1	3	2	3
20	2.2	Ranitidine hydrochloride	1	5	4	1	2	3
21	2.2	<b>Atenolol</b>	<1	2	7	<1	3	8
22	2.1	<b>Omeprazole</b>	1	3	5	1	3	3
23	2.1	<b>Albuterol</b>	2	1	4	2	3	2
24	1.9	Guanifenesin	2	<1	2	2	2	3
25	1.8	<b>Hydrocodone</b>	1	1	<1	3	2	3

Source: Adapted from Kaufman et al. 2002.<sup>19</sup><sup>a</sup>Prescription drugs in bold.<sup>b</sup>Excluding caffeine in food and beverages.

**Table 1.5** Top 10 Most Commonly Used Vitamins/Minerals and Herbal/Supplements, 1-Week Prevalence

Rank	Total Adult Use (%)	Dietary Supplements
<b>Vitamin/Mineral</b>		
	40	Any use
1	26	Multivitamin
2	10	Vitamin E
3	9.1	Vitamin C
4	8.7	Calcium
5	3.0	Magnesium
6	2.2	Zinc
7	2.2	Folic acid
8	2.1	Vitamin B <sub>12</sub>
9	1.9	Vitamin D
10	1.8	Vitamin A
<b>Herbal/Supplements</b>		
	14	Any use
1	3.3	Ginseng
2	3.2	<i>Ginkgo biloba</i> extract
3	1.9	<i>Allium sativum</i> (garlic)
4	1.9	Glucosamine
5	1.3	St. John's wort
6	1.3	<i>Echinacea augustifolia</i>
7	1.1	Lecithin
8	1.0	Chondroitin
9	0.9	Creatine
10	0.9	<i>Serenoa repens</i> (saw palmetto)

Source: Adapted from Kaufman et al. 2002.<sup>19</sup>

and 49% used at least one dietary supplement.<sup>20</sup> Twenty-nine percent used at least five prescription medications concurrently. Overall, 4% of these older adults were potentially at risk of having a major drug–drug interaction; half of these involved the use of nonprescription medications. These regimens were most preva-

lent in older men, and nearly half involved concurrent use of anticoagulants.<sup>20</sup>

Drug actions or reactions can be predictable or unpredictable. Common drug interactions in the dental setting can be minor to life threatening. Minor interactions are not absolute contraindications to drug use.

Special precautions are needed when prescribing drugs for patients who are compromised in their ability to metabolize and excrete drugs and drug breakdown products:

- liver disease;
- renal impairment;
- young children;
- the very old.

For such patients, reduced drug dosages, extended intervals between doses, or avoidance of certain drugs may be indicated. Pregnant patients require consideration of teratogenic effects of all drugs, especially during the first trimester during embryogenesis, and some systemic

medications can be found in the breast milk of nursing mothers.

Serious adverse effects may result from allergic reactions, overdosage, or drug interactions when certain medications are taken concomitantly. For safe patient management, the dentist must obtain a medication use, dietary supplement, and allergy history from the patient and have an understanding of the actions and interactions of all medications they prescribe. Drug classes used in dentistry and potential interactions with patient medications are shown in Table 1.6. Table 1.7 shows interactions with drugs prescribed in dentistry by users of the dietary supplements calcium, evening primrose, ginkgo, St. John's wort, and valerian.<sup>21</sup>

**Table 1.6** Common Dental Drug Interactions<sup>a</sup>

Patient-reported Medication	Dentist Prescribed Drug	Consequence
<b>Antimicrobial Drugs</b>		
Alcohol	Metronidazole	Disulfuram-like reaction of nausea, vomiting, headache, flushing
Antacids and iron supplements	Tetracyclines	Loss of antibacterial action of tetracyclines
Atorvastatin, simvastatin, pravastatin	Erythromycin, clarithromycin	Increased statin level precipitating possible muscle weakness and breakdown
Carbamazepine	Erythromycin, clarithromycin, doxycycline, itraconazole, ketoconazole	Increased risk of carbamazepine toxicity
Cyclosporin	Fluconazole, itraconazole, ketoconazole, amphotericin, clarithromycin	Increased risk of nephrotoxicity
Digoxin	Erythromycin, tetracyclines, itraconazole, clarithromycin	Digoxin toxicity
Lithium	Metronidazole, tetracycline	Increased lithium toxicity
Methotrexate	Penicillins	Methotrexate toxicity
Midazolam and other benzodiazepines	Erythromycin, Clarithromycin, ketoconazole, Itraconazole	Profound sedation
Oral contraceptives	Amoxicillin, erythromycin, tetracyclines, metronidazole, ampicillin, possibly other antibiotics	Contraceptive failure (low risk). (Patient should discuss with physician additional nonhormonal contraception use during antibiotic use and subsequent week)

(Continued)

**Table 1.6** (Continued)

<b>Patient-reported Medication</b>	<b>Dentist Prescribed Drug</b>	<b>Consequence</b>
Phenytoin	Fluconazole, ketoconazole, metronidazole	Increased plasma levels of phenytoin
Theophylline	Erythromycin, clarithromycin, ketoconazole, itraconazole	Theophylline toxicity
Warfarin	Erythromycin, metronidazole, tetracyclines, ketoconazole, clarithromycin, cephalosporins	Enhanced anticoagulation effect
<b>Anti-inflammatory Drugs</b>		
Alcohol	Aspirin	Increased risk of damage to gastric mucosa
Captopril, other ACE inhibitors	Aspirin, ibuprofen	Reduction in antihypertensive effect
Corticosteroids	Aspirin	Risk of salicylate toxicity on steroid withdrawal; increased risk of damage to gastric mucosa
Cyclosporin	Aspirin, NSAIDs	Increased risk of nephrotoxicity
Digoxin	Aspirin, ibuprofen	Digoxin toxicity
Heparin, warfarin	Aspirin, NSAIDs	Risk of hemorrhage
Insulin, chlorpropamide, other hypoglycemics	Aspirin	Risk of hypoglycemia
Lithium	Ibuprofen, naproxen, celecoxib	Lithium toxicity
Methotrexate	Aspirin, ibuprofen, naproxen	Methotrexate toxicity
Phenytoin	Aspirin, NSAIDs	Increased plasma levels of phenytoin
Valproic acid	Aspirin	Risk of hemorrhage; increased valproate toxicity
<b>Other Drugs</b>		
Alcohol, sedative H1 antagonists, neuroleptics, antiepileptics	Diazepam	Excessive sedation; impaired psychomotor skills; possible respiratory depression
Levothyroxine	Epinephrine	Coronary insufficiency in patients with coronary artery disease
Propranolol, other beta blockers	Epinephrine	Marked hypertension and reflex bradycardia
Tricyclic antidepressants	Epinephrine	Hypertensive reaction and possible cardiac arrhythmias

NSAID: nonsteroidal anti-inflammatory drug.

\*This list is constantly changing, with new medications and new drug interactions and toxicities reported. The dentist should consult with a contemporary electronic drug interaction program, pharmacist, or the treating physician before prescribing drugs.

**Table 1.7** Common Dietary Supplement–Dental Drug Interactions

<b>Dietary Supplement– Dental Drug</b>	<b>Potential Interaction<sup>a</sup></b>	<b>Implication</b>
<b>Calcium</b>		
<b>+Doxycycline</b>	Moderate	Reduced anti-infective effectiveness
<b>+Tetracycline</b>	Moderate	Reduced anti-infective effectiveness
<b>Evening Primrose (<i>Oenothera biennis</i>)</b>		
<b>+Aspirin</b>	Moderate	Enhanced bleeding
<b>+Ibuprofen</b>	Moderate	Enhanced bleeding
<b>Ginkgo biloba extract</b>		
<b>+Aspirin</b>	Major	Enhanced bleeding
<b>+Ibuprofen</b>	Major	Enhanced bleeding
<b>St. John's wort (<i>H. perforatum</i>)</b>		
<b>+Azithromycin</b>	Major	Possible photosensitivity reactions
<b>+Benzodiazepines</b>	Major	Reduced benzodiazepine effectiveness
<b>+Clarithromycin</b>	Major	Reduced anti-infective effectiveness
<b>+Clindamycin</b>	Major	Reduced anti-infective effectiveness
<b>+Codeine</b>	Major	Increase narcotic-induced sleep time and analgesia
<b>+Dexamethasone</b>	Major	Reduce dexamethasone effectiveness
<b>+Diphenhydramine</b>	Major	Possible photosensitivity reactions
<b>+Doxycycline</b>	Major	Reduced anti-infective effectiveness and Possible photosensitivity reactions
<b>+Erythromycin</b>	Major	Reduced anti-infective effectiveness
<b>+Hydrocodone</b>	Major	Increase narcotic-induced sleep time and analgesia
<b>+Ibuprofen</b>	Major	Possible photosensitivity reactions
<b>+Oxycodone</b>	Major	Increase narcotic-induced sleep time and analgesia
<b>+Prednisone</b>	Major	Reduced prednisone effectiveness
<b>+Tetracycline</b>	Major	Reduced anti-infective effectiveness
<b>+Zaleplon</b>	Major	Reduced zaleplon effectiveness
<b>+Zolpidem</b>	Major	Reduced zaleplon effectiveness

(Continued)



**Table 1.7** (Continued)

<b>Dietary Supplement-Dental Drug</b>	<b>Potential Interaction<sup>a</sup></b>	<b>Implication</b>
<b>Valerian</b>		
<b>+Benzodiazepines</b>	Major	Excess sedation
<b>+Codeine</b>	Major	Excess sedation
<b>+Diphenhydramine</b>	Major	Excess sedation
<b>+Hydrocodone</b>	Major	Excess sedation
<b>+Oxycodone</b>	Major	Excess sedation
<b>+Zaleplon</b>	Major	Excess sedation
<b>+Zolpidem</b>	Major	Excess sedation

Source: Adapted from Donaldson and Touger-Decker 2013.<sup>21</sup>

<sup>a</sup>Major: high severity and probable occurrence; moderate: moderate severity and probable occurrence or high severity and possible occurrence.

The dentist must ask about known drug “allergies.” If an allergy is reported, the patient should be asked what physical response resulted from taking the medication. True drug allergy is most often an immediate type I immunoglobulin E (IgE)-mediated hypersensitivity involving inflammatory mediators, such as histamine and bradykinin, released from mast cells. This is often not seen at the first exposure to a drug that creates sensitization to the allergen, with the exception of the rare anaphylactoid toxic drug reaction. The inflammatory mediator release in true drug allergy leads to vasodilation, increased capillary permeability, and bronchoconstriction. Symptoms of true allergy include skin rash, pruritis (itching), urticaria (hives), and swelling of the lips, tongue, and throat; angioedema, shortness of breath, and wheezes and stridor; and syncope and cardiovascular collapse in anaphylaxis. True allergy to ester local anesthetics (procaine–novocaine, benzocaine) most often relates to the preservative para-aminobenzoic acid; however, true allergy to amide local anesthetics (lidocaine, mepivacaine, bupivacaine, prilocaine, articaine) is rare. More common reactions to local anesthetics are vasovagal or to the epinephrine.

Other drug reactions may be known side effects that are predictable negative consequences of a therapeutic dose of the drug, such as nausea and vomiting resulting from narcotics. There are additional known effects from overdosage or sensitivity to drugs, such as apnea and oversedation from benzodiazepines, or delirium from excessive pain medication use or toxicity from use of too much local anesthetic. Drug actions important to dentistry include alteration of hemostasis (anticoagulants and platelet inhibitors), immune suppression (cytotoxic chemotherapy, immunosuppressants, corticosteroids), and ability to withstand treatment (corticosteroids).

Medications taken for systemic disease management may also have oral sequelae, a common one being xerostomia related to salivary hypofunction. Side effects that involve the oral cavity may be first detected by the dentist (e.g., antihypertensive-induced lichenoid drug reaction) or may require management by the dental team (antidepressant/antipsychotic-induced xerostomia, dilantin-induced gingival overgrowth) when alternatives are unavailable. Common or important oral consequences of systemic drugs are shown in Table 1.8.

**Table 1.8** Oral Consequences of Systemic Drugs

Oral Manifestation/Side Effect	Medications with Reported Oral Side Effect
Angioedema	ACE inhibitors, H2 blockers
Chemo-osteonecrosis of the jaw	Intravenous bisphosphonates (zoledronic acid, pamidronate, clodronate), oral bisphosphonates (alendronate, ibandronate, risedronate, etidronate, tiludronate), other bone-modifying agents, such as denosumab
Erythema multiforme	Antimalarials, barbiturates, busulfan, carbamazepine, cefaclor, chlorpropamide, clindamycin, codeine, isoniazid, H2 blockers, methyl dopa, penicillins, phenylbutazone, phenytoin, rifampin, salicylates, sulfonamides, tetracyclines
Gingival overgrowth	Calcium channel blockers (especially nifedipine and verapamil), cyclosporine, phenytoin
Glossitis/coated tongue	Amoxicillin, nitrofurantoin, tetracyclines, triamterine/hydrochlorothiazide
Lichenoid reactions	ACE inhibitors, allopurinol, chlorpropamide, chloroquine, chlorothiazide, dapsone, furosemide, gold salts, methyl dopa, NSAIDs, palladium, penicillamine, propranolol, phenothiazines, quinidine, spironolactone, streptomycin, tetracyclines, tolbutamide, triprolidine
Lupus erythematosus-like lesions	Griseofulvin, hydralazine, isoniazid, methyl dopa, nitrofurantoin, penicillin, phenytoin, primidone, procainamide, rifampin, streptomycin, sulfonamides, tetracyclines, thiouracil, trimethadione
Stomatitis/oral ulceration	Carbamazepine, dideoxycytosine, enalapril, erythromycins, fluoxetine, ketoprofen, ofloxacin, piroxicam, cancer chemotherapeutic agents
Taste alteration	ACE inhibitors, albuterol, benzodiazepines, carbimazole, chlorhexidine, clofibrate, ethionamide, dimethyl sulfoxide, d-penicillamine, gold salts, griseofulvin, guanfacin, levodopa, lincomycin, lithium, methamphetamines, methocarbamol, metronidazole, nicotine, nortriptyline, phenindione, prednisone, sertraline, tranquilizers
Tooth discoloration	Chlorhexidine, nitrofurantoin, tetracyclines
Xerostomia	Anticholinergics, anticonvulsants, antidepressants, antihistamines, antihypertensives, antineoplastics, antiparkinsonians, antipsychotics, antispasmodics, central nervous system stimulants, diuretics, gastrointestinals, muscle relaxants, narcotics, HIV protease inhibitors, sympathomimetics, systemic bronchodilators

## Ability to Tolerate Dental Care

A patient's ability to withstand dental treatment relates to both physiological and psychological stress that accompanies treatment. One response of the body to stress is release of catecholamines (epinephrine and norepinephrine) from the adrenal medulla into the cardiovascular system that results in an increased workload on the heart.<sup>22</sup> ASA classification<sup>2</sup> can provide a baseline health and stress tolerance status, with ASA 1 patients being the most stress tolerant and ASA 4 patients being the least tolerant, and most likely to need additional stress reduction techniques. Stress reduction should begin before and continue during and after dental treatment.

Physical or physiological stress of dental treatment may relate to the following:

- pain;
- time of day or length of appointment;
- dental chair position;
- use of local anesthetic with or without epinephrine.

Adequate pain control during the dental procedure is essential for patient comfort and safety. Most medically complex patients will prefer morning appointments when they are more rested and stress tolerant; however, patients with osteoarthritis may prefer short, afternoon appointments. Those with arthritis or skeletal deformities may require frequent positional changes and pillow or other supports. While full supine chair position is comfortable for many patients, those with congestive heart failure will have a limit to how far back they can be comfortably reclined without having breathing distress, and women in the third trimester of pregnancy may also need the back of the dental chair slightly elevated, with the ability to roll their torso to the left to treat or prevent supine positional hypotension. All patients will have small rises in their systolic and diastolic blood pressure and heart rate when given local anesthetic, with or without epinephrine, for dental treatment, and this effect is more marked in patients with underlying hypertension.<sup>23</sup>

Psychological stress of dental treatment may relate to:

- anxiety and
- fear.

Dental anxiety and fear are significant barriers to dental treatment. Stress reduction protocols are procedures and techniques used to minimize the stress during treatment, thus decreasing the risk to the patient.<sup>22</sup> A medical consultation may be needed to help gain information to determine the degree of risk and the modifications that might be helpful. Patient anxiety can be further reduced by the dental provider preoperatively reviewing with the patient the procedure and anticipated postoperative expectations for pain and the intended methods for obtaining adequate postoperative pain control, management of other anticipated consequences of care, and availability of and means of accessing the dentist should unanticipated after-hours questions or concerns arise.

### Stress reduction considerations

- **Anxiolytic premedication:** benzodiazepine at bedtime night before appointment and 1 h prior to appointment
- **Appointment scheduling:** early in the day
- **Minimize waiting time:** in waiting room and dental chair
- **Preoperative and postoperative vital signs:** blood pressure, heart rate and rhythm, respiratory rate, pain score
- **Sedation during treatment:** iatrosedation (music and video distraction, hypnosis), nitrous oxide–oxygen analgesia or pharmacosedative procedures including oral, inhalational, intramuscular, intranasal, or intravenous (minimal or moderate) sedation or general anesthesia
- **Treatment duration:** short appointments



## IV. Dental Management Modifications

When a medical risk assessment screening is completed, the dental provider develops an awareness of the medical complexity or risk status of the patient and can predict the possible complications related to the planned dental procedures. Complications may vary from minor to major or life threatening. Minor complications can be prevented or managed easily at home or at chairside, while major complications may require medical management and possible hospitalization. An understanding of the patient's underlying medical condition allows the dental provider to recommend modification before, during, or after the dental procedures in order to safely provide dental care.

Examples of modification *before dental treatment* include the following:

1. antibiotic prophylaxis;
2. scheduling the treatment at a certain time of day or day of the week around medical therapy such as insulin management, chemotherapy, or hemodialysis;
3. altering medication timing or dose, in consultation with the patient's physician;
4. steroid supplementation;
5. preoperative drug use (e.g., bronchodilator or hemostasis supportive medications);
6. preoperative blood product administration;
7. verification of last food intake;
8. obtaining day-of-procedure baseline blood pressure and heart rate;
9. verification of metabolic hemostasis with laboratory tests, such as glycosylated hemoglobin (HbA1C), blood glucose from finger stick, prothrombin time/international normalized ratio, platelet count, white blood cell count with absolute neutrophil count;
10. obtaining hyperbaric oxygen wound-healing enhancement;
11. defer care due to complexity;
12. choice of setting—outpatient clinic or operating room setting.

Examples of modification *during dental treatment* include the following:

1. stress management with anxiolytic oral agents or nitrous oxide–oxygen;
2. providing physical supports or rest breaks;
3. limiting dosage of local anesthetic;
4. avoiding use of certain medications;
5. maintaining adequacy of pain control;
6. assuring aseptic surgical technique or using preoperative oral antiseptic rinse;
7. application of local hemostatic agents;
8. using supplemental oxygen by nasal cannula.

Examples of modification *after dental treatment* include the following:

1. prescribing a therapeutic course of antibiotics;
2. use of postoperative antifibrinolytics;
3. postoperative stress management;
4. maintaining adequacy of pain control;
5. avoiding use of certain medications;
6. assuring appropriate and understood postoperative instructions.

## V. Recommended Readings and Cited References

### Recommended Readings

- Cianco S. The ADA/PDR Guide to Dental Therapeutics, 5th ed. 2009. American Dental Association, Chicago, IL.
- Glick M (Ed.). Burket's Oral Medicine. 12th Edition. PMPH-USA, Ltd. Shelton, CT. 2015
- Hersh EV. Adverse drug reactions in dental practice: interactions involving antibiotics. *J Am Dent Assoc* 1999;130(2):236–51.
- Hersh EV, Moore PA. Adverse drug interactions in dentistry. *Periodontol* 2000 2008;46:109–42.
- Lockhart PB, Hong CHL, van Diermen DE. The influence of systemic diseases on the diagnosis of oral diseases: a problem-based approach. *Dent Clin North Am* 2011;55(1):15–28.
- Scully C, Bagan JV. Adverse drug reactions in the orofacial region. *Crit Rev Oral Biol Med* 2004;15(4):221–39.

Yuan A, Woo SB. Adverse drug events in the oral cavity. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2015;19(1):35–47.

## Cited References

1. National Center for Health Statistics. Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville, MD. 2014. Available at: <http://www.cdc.gov/nchs/data/abus/abus13.pdf#018>. Accessed May 10, 2015.
2. American Society of Anesthesiologists. ASA Physical Status Classification System. Available at: <http://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system>. Accessed May 11, 2015.
3. Smeets EC, de Jong KJ, Abraham-Inpijn L. Detecting the medically compromised patient in dentistry by means of the medical risk-related history. A survey of 29,424 dental patients in the Netherlands. *Prev Med* 1998;27(4):530–5.
4. Brady WF, Martinoff JT. Validity of health history data collected from dental patients and patient perception of health status. *J Am Dent Assoc* 1980;101(4):642–5.
5. Ertas ET, Sisman Y. Detection of incidental carotid artery calcifications during dental examinations: panoramic radiography as an important aid in dentistry. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2011;112(4):e11–17.
6. Abebe W, Herman W, Konzelman J. Herbal supplement use among adult dental patients in a USA dental school clinic: prevalence, patient demographics, and clinical implications. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2011;111(3):320–5.
7. Brennan MT, Valerin MA, Noll JL, Napeñas JJ, Kent ML, Fox PC, et al. Aspirin use and post-operative bleeding from dental extractions. *J Dent Res* 2008;87(8):740–4.
8. Wahl MJ. Dental surgery and antiplatelet agents: bleed or die. *Am J Med* 2014;127(4):260–7.
9. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. *J Am Dent Assoc* 2000;131(1):77–81.
10. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *J Am Dent Assoc* 2007;138(5):652–5.
11. Zhang W, Daly CG, Mitchell D, Curtis B. Incidence and magnitude of bacteraemia caused by flossing and by scaling and root planing. *J Clin Periodontol* 2013;40(1):41–52.
12. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *J Am Dent Assoc* 2008;139(Suppl.):3S–24S. Erratum in: *J Am Dent Assoc* 2008;139(3):253.
13. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, et al. A summary of the update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *J Am Dent Assoc* 2011;142(2):159–65.
14. Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, et al. Nonvalvular cardiovascular device-related infections. *Circulation* 2003;108(16):2015–31.
15. Watters W III, Rethman MP, Hanson NB, Abt E, Anderson PA, Carroll KC, et al. Prevention of orthopaedic implant infection in patients undergoing dental procedures. *J Am Acad Orthop Surg* 2013;21(3):180–9.
16. Jevsevar DS. Shared decision making tool: should I take antibiotics before my dental procedure? *J Am Acad Orthop Surg* 2013;21(3):190–2.
17. Sollecito TP, Abt E, Lockhart PB, Truelove E, Paumier TM, Tracy SL, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: evidence-based clinical practice guideline for dental practitioners—a report of the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc* 2015;146(1):11–16.



18. Lockhart PB, Loven B, Brennan MT, Fox PC. The evidence base for the efficacy of antibiotic prophylaxis in dental practice. *J Am Dent Assoc* 2007;138(4):458–74.
19. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. *JAMA* 2002;287(3):337–44.
20. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA* 2008;300(24):2867–78.
21. Donaldson M, Touger-Decker R. Dietary supplement interactions with medications used commonly in dentistry. *J Am Dent Assoc* 2013;144(7): 787–94.
22. Malamed SF. Knowing your patients. *J Am Dent Assoc* 2010;141(Suppl. 1):3S–7S.
23. Bader JD, Bonito AJ, Shugars DA. A systematic review of cardiovascular effects of epinephrine on hypertensive dental patients. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2002;93(6):647–53.